Rhythm Pharmaceuticals (RYTM) Profit After Tax (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Profit After Tax for 11 consecutive years, with -$55.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 9.46% year-over-year to -$55.6 million; the TTM figure through Mar 2026 stood at -$202.7 million (down 19.21% YoY), while the FY2025 annual figure was -$196.5 million, up 24.58% from the prior year.
• Profit After Tax fell to -$55.6 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$32.3 million in Q2 2024 and bottomed at -$141.4 million in Q1 2024.
• Historically, Profit After Tax has averaged -$51.8 million across 5 years, with a median of -$46.6 million in 2025.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 220.6% — and 2025, when it jumped 64.04%.
• Rhythm Pharmaceuticals' Profit After Tax stood at -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then retreated by 3.98% to -$43.3 million in 2024, then decreased by 9.73% to -$47.5 million in 2025, then fell by 17.12% to -$55.6 million in 2026.
• Business Quant data shows RYTM's Profit After Tax at -$55.6 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.9 million in Q3 2025.